NAVIGEN, INC. — Department of Health and Human Services SBIR Phase I: NHLBI
NAVIGEN, INC. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $268,075
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NHLBI
- Solicitation
- PA18-574
- NAICS
- —
- Place of performance
- UT
- Period
- 2019-09-24 → 2020-09-19
Description
SUMMARYInfluenzavirusinfectionisoneofthemostcommonacuterespiratorydiseasesandremainsoneofthelargestdiseaseburdensonhumanswithsevereprimaryviralpneumoniaoftenresultingindeathThepathogenicityofinfluenzaincludesahostresponsethatcanincludeaseveresystemicinflammatoryreactioncytokinestormandensuingvascularleakVascularleakisafundamentalelementinthepathogenesisofcirculatoryshockandmultipleorganfailurewhichcanleadtodeathininfluenzapatientsThelaboratoriesofDrDean Licofounder and former Chief Scientific Officer of Navigenand DrShannon Odelbergalong withNavigenhavedemonstratedthatvascularleakassociatedwithinflammationismediatedbyactivationofthesmall GTPaseARFa common nodal point in the signaling pathways of several inflammatory cytokines andgrowth factorsNavigen s objective is to reduce morbidity and mortality associated with influenza infections bymodifyingthishostresponseSpecificallyweproposetoevaluatetheefficacyofoursmallmoleculeARFinhibitorswiththehypothesisthatinhibitionofARFwillreducevascularleakelicitedbytheinfectionwhilehaving no adverse effect on immunitybased clearance of the virusNARRATIVEInfluenzainfectionremainsoneofthelargestdiseaseburdensonhumanswithsevereprimaryviralpneumoniaoftenresultingindeathThepathogenicityincludesahostresponsethatcanincludeaseveresystemicinflammatoryreactionandensuingvascularleakNavigenhasdemonstratedthatvascularleakassociated with inflammation is mediated by activation of the small GTPase ARFand proposes to evaluate itssmallmolecule ARFinhibitors in a mouse model of H Ninfection